Pelthos Therapeutics Inc.

Clinical/early-stage biotech — dermatology commercial-launch (ZELSUVMI), heavy burn, funded.

Strengths

• Liquidity — current ratio 2.1 (28th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Going concernRisks Related to Our Financial Condition and Capital Needs The report of the independent registered public accounting firm on our 2024 financial statements contained a going concern qualification
• Exec changeRecent 8-K item 5.02 8-K ↗
• Net lossNet loss (net margin -257.9%)
• Cash burnNegative free cash flow (-22.7M)
• Auditor changeRecent 8-K item 4.01 8-K ↗
• Customer concentration~90% of revenue from one customer/distributor — As of December 31, 2025, three of the Company’s wholesaler customers accounted for 90% of its total gross accounts receivable balance at 38%, 31% and 21%, respectively
• Buying back stockNet buyback — share count -56%/yr over 1y
• Insider buyingInsider buying — 2 open-market buy(s) by 1 insider(s) (~$999,983, last 6mo) Form 4 ↗
• Notable holderHeld by 1 notable fund(s): VANGUARD GROUP INC (as of 2025-12-31)
• Insider sellingInsider selling — 11 open-market sale(s) by 5 insider(s) (cluster of 5 insiders, last 6mo) Form 4 ↗
• Pending merger63 Results of Operations On July 1, 2025, Channel, Merger Sub (a wholly owned subsidiary of Channel), LNHC, and solely for the purposes of Article III within the Merger Agreement, Ligand consumma